Description: Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Home Page: www.twistbioscience.com
681 Gateway Boulevard
South San Francisco,
CA
94080
United States
Phone:
800 719 0671
Officers
| Name | Title |
|---|---|
| Dr. Emily Marine Leproust Ph.D. | Co-Founder, Chairman & CEO |
| Dr. Patrick John Finn Ph.D. | Pres & COO |
| Mr. James M. Thorburn | Chief Financial Officer |
| Dr. William Charles Banyai Ph.D. | Sr. VP of Advanced Devel., GM of Data Storage & Director |
| Mr. Kevin B. Yankton | VP & Chief Accounting Officer |
| Mr. Siyuan Chen | Chief Technology Officer |
| Dr. Aaron K. Sato Ph.D. | Chief Scientific Officer |
| Mr. Dennis Cho | Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer |
| Ms. Paula Green | Sr. VP of HR |
| Ms. Erin Smith | Sr. VP of Gov. Affairs & Public Policy |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9106 |
| Price-to-Sales TTM: | 6.472 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 989 |